Key Performance Indicators and Performance in Relation to the GRI and ATMI

	2007	2006	2005
Economic indicators
Sales (US$M)	24,197.7	22,636.0	22,011.9
Annual cash dividend paid per share (US$)	1.52	1.52	1.52
Global tax expense as reported on income statement (US$M)^[a]	95.3	1,787.6	2,732
Researching needed new medicines and vaccines to address unmet needs
Merck's investment in R&D programs (US$)^[b]	4.9 bn	4.8 bn	3.8 bn
Number of new products approved (Number of compounds in the pipeline—Phases I-III plus under regulatory review)	2 (49)	5 (57)	2 (58)
% of top 20 global burdens of illness addressed by our products and pipeline (as defined by WHO and excluding accidents, premature birth and self-inflicted injuries)	60	N/R	N/R
Phase II-V clinical trials conducted (in number of countries)	58 (54)	50 (49)	N/R
Manuscripts of clinical trial results and related papers submitted to peer reviewed journals	172	172	N/R
Improving access to medicines, vaccines and health care
Number of Merck products for which not-for-profit prices are offered to least developed countries	6	2	2
Number of patients on Merck ARV therapy—all formulations, all products (% in developing world)	763,118 (91)	701,391 (93)	N/D
% of total patients on Merck ARVs estimated to be children taking pediatric formulations of Merck´s ARVs	15	19	N/D
Number of countries where Merck has committed to no-profit prices for ROTATEQ and GARDASIL	72	N/R	N/R
Number of low and middle income countries using Merck's vaccines in their public sectors	11	N/R	N/R
Number of country registrations of GARDASIL and ROTATEQ globally (and cumulative)	62 (164)	101 (102)	1
Product donations $US million (% in the developing world)^[c]	766 (79)	768 (58)	979 (45)
Millions of treatments approved for river blindness through the MECTIZAN Donation Program (at 3 tablets per treatment)	128	118	114
Patients utilizing Merck's Patient Assistance Program^[d] (total value of Merck medicines dispensed under Merck's PAP)	350,000 ($161.5m)	540,240 ($326m)	730,000 ($502m)
Major PPPs to improve access to medicines, vaccines or health care^[e]	13	12	10
Ensuring confidence in the safety and quality of our products
Product recalls in United States	2	0	1
Conducting ourselves ethically and transparently
% of required employees who took Know the Code training^[f]	90	N/A	N/A
% of response to disclosure statement on conflicts of interest	97	95	93
Calls to the Merck AdviceLine	149	77	80
Calls to the Office of Ethics/Ombudsman	600	597	770
% of substantiated (including alternate findings) allegations to concerns/issues raised in connection with our Code of Conduct through AdviceLine or Office of Ethics/Ombudsman^[g]	9.5	8.3	10.2
Merck operations at significant risk of forced or compulsory labor, incidents of child labor, or violations of the right to exercise freedom of association and collective bargaining	0	0	N/D
Managing our environmental footprint
Environmental inspections	76	88	N/D
Environmental events^[h]	60	28	32
Environmental notices of violation	13	11	N/D
Environmental fines paid (US$)	31,515	10,652	281,025
Total energy use (million BTUs x 106)	15.2	15.5	17.5
Energy intensity (MMBTU/sq ft)	0.52	0.54	0.61
Total GHG emissions (as C0₂ eq—million metric tons)^[i]	1.36	1.36	1.44
Total water usage (billion gallons) [% reduction versus prior year]	8.8 [8.3]	9.6 [5]	10.1 [13.6]
Emissions of ozone-depleting substances (metric tons)^[K]	1.4	N/D	N/D
Nitrogen oxides (NOx) emissions (metric tons)	303	306	468
Sulfur oxides (SOx) emissions (metric tons)	58	76	84
Emissions of volatile organic compounds (VOCs) (metric tons)^[j]	401	427	411
TRI emissions (metric tons to air and water)	270	242	163
Hazardous waste generated in metric tons (% recycled)	54,000 (23)	62,300 (29)	60,900 (37)
Nonhazardous waste generated in metric tons (% recycled)^[I]	31,600	N/D	N/D
Valuing our employees
Number of employees	59,800	60,000	61,000
Total compensation paid to employees/payroll excluding benefits ($bn)	5.56	5.14	4.84
% of women in workforce (globally)	48	49	49
% of women on the Board	23	25	25
% of women in executive roles (U.S.)	27	26	28
% of under-represented ethnic groups on the Board	17	17	17
% of under-represented ethnic groups in executive roles (U.S.)	11	12	11
% of employee response rate to Merck Culture Assessment survey^[m]	72	77	N/A
Overall turnover rate	10.7	11.9	10.6
Safety inspections	41	65	N/D
Notices of safety violations/citations	3	8	N/D
Safety fines paid in $ (Number of fines)	1,500 (1)	1,975 (2)	1,000 (2)
Lost-Time Incident Rate (LTIR)^[n,o]	0.48	0.43	0.44
LTIR % change	12	-2.3	-14
Reportable Injury Rate (RIR)^[n]	1.12	1.11	1.21
RIR % change	0.9	-8.3	-25.8
Fatalities	1	0	0
Accidents Per Million Miles (APMM)	9.64	9.92	10.4
Supply chain management
% of spending on diverse suppliers in the U.S.	12	8	5
Percentage of completed PSCI surveys received from existing external manufacturers (number of surveys)^[p]	54 (64)	N/A	N/A
Percentage of facility visits conducted of potential external manufacturers of new business (number of visits)	100 (19)	N/A	N/A
Philanthropy
Merck's philanthropic contributions (total cash and product) (US$M)^[c]	828	826	1,039
Cash contributions (US$M)	62	58	60
Advocacy and outreach
Political contributions (US, CAN, AUS) US$^[q]	US: 470,625	US: 611,975	US: 337,140
	AUS: 19,195	AUS: 20,292	AUS: 12,137
	CAN: 58,396	CAN: 45,765	CAN: 46,700
Portion of dues that major U.S.-based trade associations report to us as being used for advocacy and/or political activities in the U.S.(US$) where dues are > $50,000^[r]	6.9 million paid to 8 groups	N/A	N/A

	KEY
	N/A: not applicable; N/D: no data; N/R: not reported; many of these indicators are new for Merck and for this reason some prior year data points are not reported.
^[a]	The tax expense in 2007 reflected the reduction in domestic pre-tax income primarily resulting from the U.S. VIOXX settlement charge. For more information, please see our Form 10-K for the year ended December 31, 2007.
^[b]	Research activities and investments include all Merck divisions.
^[c]	We value our product donations based on the U.S. wholesale price.
^[d]	Totals include the U.S. Merck Vaccine Patient Assistance Program and are based on the U.S. wholesale price.
^[e]	Major is defined as with an investment by Merck of more than $500,000 per year and/or engagement with a national government. Therefore, these include MDP, MMOP, AAI, ACHAP, C-MAP, MVNA, ROTATEQ Partnership, GARDASIL Access Program, Nursing Libraries, MCAN, Diabetes Alliance, Blueprint and DHL Partnership.
^[f]	Know the Code was first implemented globally in 2007.
^[g]	When Merck substantiates allegations of ethical misconduct, it imposes a variety of disciplinary actions on those responsible for the misconduct, such as dismissal from the Company, issuance of final written warning letters and financial penalties.
^[h]	The increase in the number of events is due primarily to a modified regulatory interpretation in late 2006 that requires reporting for spills that were not previously required to be reported.
^[i]	In accordance with U.S. EPA Climate Leaders protocol, GHG generation baseline data have been adjusted to remove facilities that have been sold. In addition, Merck recalculated its GHG emissions for the years 2004 through 2007 based on new emissions factors released by EPA in April of 2007 (based on 2004 energy generation data), which resulted in reporting increased emissions for 2004, 2005 and 2006.
^[j]	Previously reported VOC data have been corrected.
^[k]	Data unavailable for a site sold at the end of 2007.
^[l]	2007 was the first year we collected nonhazardous waste generation and recycling data. Data should be considered estimates.
^[m]	Survey not conducted prior to 2006.
^[n]	LTIR/RIR: Calculated per OSHA methodology.
^[o]	Data reflect a correction from previous reports also impacting 2003 and 2004 LTIR, 0.55 and 0.51, respectively.
^[p]	Pharmaceutical Supply Chain Initiative (PSCI) survey first implemented in 2007.
^[q]	Total reflects corporate contributions; employee contributions through the Merck PAC are not included.
^[r]	Because the U.S. tax law that requires this reporting does not apply outside the United States, trade associations that are not subject to this do not provide break-outs of lobbying expenditures from membership dues. Thus, at this time, Merck is unable to report these data for such lobbying expenses in other countries.

The content on this page was last modified on October 24, 2008.

Summary of Key Performance Indicators